|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK Global PS] MW&RESºÎ¼ MW ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.11 |
|
|
(ÁÖ)¸ÞµðÇïÇÁ¶óÀÎ |
Clinical QA Team(Ç°Áúº¸Áõ) °æ·Â»ç¿ø/ÆÀÀå ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
2³â¡è |
ä¿ë½Ã |
12.01 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
PV Specialist ¸ðÁý(½ÅÀÔÁö¿ø°¡´É/1³â°è¾à±Ù¹«)
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.16 |
|
|
(ÁÖ)¸ÞµðÇïÇÁ¶óÀÎ |
(ÁÖ)¸ÞµðÇïÇÁ¶óÀÎ ±â¾÷ ±âȹ ¹× È«º¸/¸¶ÄÉÆà ´ã´çÀÚ ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
±¤°í/È«º¸/PR/»çº¸ |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.05 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK Global PS] PS ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.11 |
|
|
(ÁÖ)¸ÞµðÇïÇÁ¶óÀÎ |
Clinical QA Team(Ç°Áúº¸Áõ) °æ·Â»ç¿ø ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
2³â¡è |
ä¿ë½Ã |
11.17 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
SCºÎ¼ RA °æ·Â ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
12.05 |
|
|
Çѱ¹Organon |
Çѱ¹Organon Market Access ´ã´çÀÚ ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
01.15 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
BDºÎ¼ BD Manager ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
1³â¡è |
ä¿ë½Ã |
08.03 |
|
|
(ÁÖ)À¯À¯Á¦¾à |
°³¹ßÆÀ °æ·ÂÁ÷ ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
6³â¡è |
ä¿ë½Ã |
02.02 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK global PS] SP / ERA / PL ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
12.02 |
|
|
Çѱ¹MSD µ¿¹°¾àÇ° |
[Çѱ¹MSDµ¿¹°¾àÇ°]-Swine Key Account Manager
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
3³â¡è |
ä¿ë½Ã |
05.13 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
ERºÎ¼ ÆÀÀå / ERA °æ·Â/ PL/ A.PL ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
1³â¡è |
ä¿ë½Ã |
10.05 |
|
|
Çʸ³½º ÄÚ¸®¾Æ |
Philips Korea-Regulatory Affairs Country Lead-South Kore
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¼ö½Ãä¿ë |
10³â¡è |
ä¿ë½Ã |
11.10 |
|
|
LSK Global PS |
[LSK Global PS] SCºÎ¼ RA °æ·Â ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
11.03 |
|